Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Scripts who wrote (1143)	12/21/2000 10:24:39 PM
From: Ian@SI	Read Replies (2) \| Respond to of 1321

Ed, QLT did the unforgivable. It missed its earnings guidance by about less than 2.5% plus some currency translation (another 5%). So the street, in its infinite wisdom, has decided that the stock price is only worth 1/3 what they estimated a few months ago. Next earnings are unlikely to help much. Reimbursement issues in Europe are taking longer than expected to sort out. Leerink continues to doubt the growth story even though Visudyne has had the best growth profile of any Ophthalmologic treatment ever. And that's only for the wet form of AMD. We can realistically expect the label to be expanded relatively soon. I still expect QLT to approach $1B revenues (its share) within 3 or 4 years. In any case, we already know that the next earnings report is not going to be earthshaking. Nevertheless, the growth story remains intact. IMO, Ian.